On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). Its complete genome was sequenced by the laboratory of respiratory infection viruses at the Institut Pasteur on 29 January 2020 in France. This will allow the identification of antigenic structures involved in the immune response and the development of serological diagnostic tests. Many questions are being asked about this new virus and the infection it causes, including questions about the percentage of asymptomatic and pauci-symptomatic forms. Serological studies can provide answers to these questions. There is no serological test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut Pasteur is working on its development. This study proposes to carry out a collection of samples taken from subjects who travelled to China before the epidemic outbreak or suspected of being infected with SARS-CoV-2. As soon as it is available, serology will be performed on the collected samples.
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). This new virus is presented as the causative agent of pneumonias. Its complete genome was sequenced by the laboratory of respiratory infection viruses at the Institut Pasteur on 29 January 2020 in France. This will allow the identification of antigenic structures involved in the immune response and the development of serological diagnostic tests. Many questions are being asked about this new virus and the infection it causes, including questions about the transition from animal to human occur, the beginning of viral circulation in humans, the period of contagiousness, the percentage of asymptomatic and pauci-symptomatic forms. Serological studies can provide answers to these questions. There is no serological test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut Pasteur is working on its development. This study proposes to carry out a collection of samples taken from subjects who travelled to China before the epidemic outbreak or suspected of being infected with SARS-CoV-2. As soon as it is available, serology will be performed on the collected samples.
Study Type
OBSERVATIONAL
Enrollment
5,000
Blood samples for serological tests
Blood samples, saliva, nasopharyngeal swab for serological tests
CHU Amiens-Picardie
Amiens, France
EHPAD Villa Concorde
Asnières-sur-Seine, France
CHU François Mitterand
Dijon, France
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, France
CHU Limoges
Limoges, France
Hôpital de la Croix Rousse
Lyon, France
EHPAD Les Etangs
Mennecy, France
CHRU de Nancy
Nancy, France
Hôpitaux de Brabois
Nancy, France
CHR Orléans
Orléans, France
...and 11 more locations
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.
Description of the serological status of individuals by different detection tests
Time frame: One year
Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies
Proportion of asymptomatic subjects into seropositive population
Time frame: One year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.